Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

Abbott Laboratories (ABT) reports Q2 earnings on July 15, with analysts expecting EPS of $1.28 (+1.6%) and revenue of $12.52B (+12.4%). Growth is driven by the Exact Sciences acquisition, particularly its CancerGuard test. While Seeking Alpha rates ABT a Buy based on long-term MCED potential, Baird models more modest comparable growth of 4-4.5% for Q2. Despite beating estimates historically, ABT's stock has declined 29% year-to-date.